The FDA has granted fast track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration, according to a press release from Gyroscope Therapeutics.
The designation is for patients with specific mutations in the complement factor I gene and low levels of CFI protein in their blood. Enrollment is underway in the EXPLORE phase 2 study to evaluate GT005 in these patients.
“Dry AMD is a life-altering diagnosis, and there are currently no FDA-approved medicines available. Research suggests people with dry AMD who have certain (Read more...)